CD8A and rheumatic disorder: Interestingly, after complete COVID-19 vaccination S-specific CD8 T-cell response rate was also higher in rheumatic disease patients receiving anti-CD20 therapy (81.8%) than in immunocompetent controls (66.7%) (44).